Abstract
Objective
Radioiodine (I-131) therapy for hyperthyroidism is a well-established and safe treatment option. This study aimed to investigate the relationship between the computed tomography (CT) value and the function and volume of the thyroid gland by identifying the factors that induce changes in the CT value of patients with hyperthyroidism.
Methods
This retrospective study evaluated 38 patients with Graves’ disease and 10 patients with Plummer disease. To obtain the mean CT value and volume of the thyroid gland, the entire thyroid gland was set as the region of interest. A test dose of 3.7 MBq I-131 was administered before initiating I-131 therapy, and the radioiodine uptake (RIU) rate was assessed after 3, 24, 96, and 168 h. An approximate curve was plotted based on the RIU values obtained, and the effective half-life (EHL) was calculated. The correlation between the mean CT value and the volume of the thyroid gland, 24-h RIU, EHL, and the free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and TSH receptor antibody (TRAb) levels was evaluated.
Results
The CT value exhibited a significant positive correlation with EHL in patients with Graves’ disease (r = 0.62, p < 0.0001) as well as patients with Plummer disease (r = 0.74, p < 0.05). However, it did not display any correlation with the remaining parameters.
Conclusion
The CT value is significantly correlated with EHL, suggesting that it reflects thyroid function and is mainly related to the factors associated with iodine discharge.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Iodine is stored in the thyroid gland for the synthesis of thyroid hormones. Therefore, thyroid glands, which contain a large amount of iodine with a high atomic number, tend to exhibit a relatively high computed tomography (CT) value. The normal thyroid CT value is approximately 110 Hounsfield units (HU) [1, 2]. In contrast, the CT value of patients with Graves' disease, a form of hyperthyroidism, is lower than the normal CT value [2]. Although the CT value may reflect thyroid function [1, 3,4,5,6]the relationship between the CT value and thyroid function has not yet been fully investigated, partly due to concerns regarding radiation exposure to patients.
The main treatment options for hyperthyroidism include medication (such as beta-blockers or antithyroid drugs), radioiodine therapy (iodine-131), and thyroidectomy [7]. Among these, I-131 therapy stands as a well-established treatment with recognised effectiveness [8, 9]. In I-131 therapy, factors such as the radioiodine uptake rate (RIU), the effective half-life (EHL), and the thyroid volume significantly influence the effectiveness of the treatment [10,11,12]. Therefore, it is important to evaluate thyroid function and volume beforehand and administer an appropriate amount of I-131. However, measuring the iodine uptake rate and the effective half-life is a cumbersome process, requiring the intake of I-131 for testing purposes and multiple measurements [12]. If the thyroid CT value is determined to be related to thyroid function and morphology, it could potentially serve as an alternative to the complex methods required for thyroid function evaluation.
At our hospital, plain CT imaging is conducted to measure thyroid volume, allowing us to retrospectively examine the thyroid CT value using these images. In this study, we investigated the relationship between thyroid function and volume and the thyroid CT value in patients with Graves’ disease and Plummer disease to determine whether the thyroid CT value reflects thyroid function and volume.
Patients and methods
Patients
Thirty-eight patients with Graves’ disease (male, n = 6; female, n = 32; age, 42.1 ± 13.7 years) and 10 patients with Plummer disease (male, n = 3; female, n = 7; age, 59.1 ± 14.5 years) who received their first I-131 therapy between March 2018 and December 2019 were included in this retrospective analysis.
Treatment schedule
The administration of antithyroid medication and potassium iodide was discontinued 2 weeks before I-131 therapy. The free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and TSH receptor antibody (TRAb) levels were measured once before treatment. FT3, FT4, and TSH levels were determined using a CLEA kit (Abbott Diagnostic Medical, Chicago, IL, USA; normal range: FT3, 1.68–3.67 pg/mL; FT4, 0.70–1.48 ng/dL; TSH, 0.35–4.94 μIU/mL). TRAb levels were determined using an ECLES Kit (Roche Diagnostic Medical, Basel, Switzerland; (normal range: < 2.0 IU/L). All patients with Graves’ and Plummer disease who received I-131 therapy at our hospital underwent non-contrast CT scanning of the neck (Aquilion PRIME SP; Canon Medical Systems, Tokyo, Japan) for thyroid volumetry. The CT imaging conditions were as follows: tube voltage, 120 kVp; tube current, determined via an automatic exposure mechanism. CT images were reconstructed with a slice thickness of 5 mm, and a nuclear medicine specialist manually placed the region of interest (ROI) over the entire thyroid gland on the CT images (Fig. 1). The thyroid volume was determined using the area of the thyroid gland and the slice thickness in each slice, and the sum of the thyroid volumes obtained from all slices was used as the thyroid volume. The average CT value within the ROI placed over the entire thyroid gland was calculated (Fig. 1). The average CT value for the entire thyroid gland was calculated, excluding slices showing calcification in the thyroid gland or obvious changes in the CT value due to artefacts. RIU measurements were performed as follows. A test dose of 3.7 MBq I-131 (RADIOCAP; FUJIFILM Toyama Chemical Co., Ltd., Tokyo, Japan) was orally administered before initiation of I-131 therapy, and the RIUs of the thyroid gland were measured after 3, 24, 96, and 168 h. A thyroid uptake system (AZ-800; Anzai Medical, Tokyo, Japan) equipped with NaI crystals was used to acquire the measurements. Before measurements in patients, a neck phantom (ORINS Standard thyroid uptake phantom; Abbott) was evaluated. The I-131 capsule (activity = 3.7 MBq) was placed in the phantom and counts were taken (S). Background measurements were performed with the neck phantom shielded by a lead plate (B_1). Next, the thyroid gland in patients was measured twice, once without shielding (T) and once with shielding by a lead plate (B_2). From each measurement, RIU was calculated using Eq. 1.
The 24-h RIU was calculated by correcting for attenuation so that the total count in the thyroid region was equal to the count at the time of administration. EHL was calculated by exponential approximation of the ratio of counts at each time point, obtained by Eq. 1 (Fig. 2). Because thyroid RIU generally reaches its maximum at around 24 h, EHL was calculated using RIU after 24, 96, and 168 h, when the thyroid gland was in the excretory phase. The CT imaging and RIU and EHL measurements were performed from 1 month to 1 week before the I-131 therapy. Blood tests were performed on the day of I-131 therapy before I-131 administration.
Statistical analysis
Data were analysed using the statistical software EZR [13]. Pearson’s correlation and linear regression analyses were conducted using the mean CT value of the respective tracers. Regression analysis was conducted using the parameters with significant correlations, and regression equations were calculated. Statistical significance was set at p < 0.05.
Results
Table 1 summarises the details of patients with Graves’ disease, including the CT value, thyroid volume, RIU, EHL, and the FT3, FT4, TSH, and TRAb levels.
The CT value exhibited a significant positive correlation with EHL in patients with Graves’ disease (r = 0.62, p < 0.0001) (Fig. 3). The regression equation was as follows: EHL = 0 0.09 × CT value + 1.45.
The CT value exhibited no correlation with the thyroid volume (r = 0.04, p = 0.82), 24-h RIU (r = − 0.23, p = 0.19), and FT3 (r = − 0.02, p = 0.90), FT4 (r = 0.01, p = 0.93), TSH (r = − 0.17, p = 0.553) levels, and TRAb levels (r = − 0.14, p = 0.41) (Fig. 4). As the FT3 and FT4 levels exceeded the upper limit of measurement (FT3, 30 pg/mL; FT4, 6 ng/dL) in two and one patients, respectively, the correlation coefficients were calculated after excluding each case. Similarly, the correlation coefficients were calculated after excluding 23 patients with TSH levels below the lower limit of measurement (0.003 µIU/mL).
In addition, the CT value displayed a significant positive correlation (r = 0.74, p < 0.05) with EHL in patients with Plummer disease (Fig. 5). The TSH levels were below the detection limit in nine of the 10 patients. All patients tested negative for TRAb. The regression equation was EHL = 0.07 × CT value + 3.17. Moreover, the CT value exhibited no correlation with the thyroid volume (r = − 0.04, p = 0.92), 24-h RIU (r = − 0.60, p = 0.07), and FT3 (r = − 0.45, p = 0.20) and FT4 (r = − 0.33, p = 0.35) levels.
Discussion
The thyroid gland comprises numerous follicles, each containing thyroid follicular cells arranged in a circular pattern surrounding a colloid containing thyroid hormones produced from thyroglobulin and iodide. The secretion of the thyroid hormone is regulated by TSH [7]. On CT images, the CT value of the thyroid gland is approximately 100–110 HU, higher than that of soft tissues [1, 2]. This elevation in the CT value may be attributed to the presence of several colloids containing iodine in the thyroid gland. Notably, a strong correlation has been reported between the iodine concentration in the thyroid tissue and the CT value [1]. In the present study, the CT value exhibited a significant positive correlation with EHL, which is the rate of iodine accumulation or elimination from the thyroid gland. If the EHL is short and the duration from RIU to elimination is rapid, iodine is not stored in the thyroid tissue for a long duration. Therefore, patients with low CT values are likely to have a higher RIU rate for elimination in the thyroid gland. The iodine concentration in the thyroid gland is strongly correlated with the CT value; however, factors other than iodine concentration can also affect the CT value. Imanishi et al. reported that a decrease in the CT value indicates a decrease in the colloidal area associated with a decrease in iodine concentration within the colloid and an increase in the ratio of follicular cells and interstitial structures to the total thyroid gland [5]. Han et al. reported that the CT value is correlated with the standardised uptake value on positron emission tomography images, and that the CT value is correlated with inflammation in the thyroid tissue [4]. The CT values of follicular cells and interstitial tissue are comparable with those of soft tissue, resulting in lower CT values than those for normal thyroid tissue. A lower CT value may also reflect an increase in the ratio of follicular cells and interstitial tissue to total thyroid tissue.
In addition, the CT value is correlated with EHL and reflects the iodine metabolic capacity of the thyroid gland. EHL is an index required for determining the administered radioactivity of I-131 therapy. EHL should be measured at least twice within 8 days of administration of the I-131 test dose and repeated three or more times for accurate measurement. A fixed value is sometimes used to estimate the absorbed dose for I-131 therapy, as the measurement of the EHL is complicated. However, because calculating the absorbed dose with EHL as a fixed value can lead to errors, the EANM guidelines do not recommend determining radioactivity without considering thyroid volume and iodine kinetics [12]. Moreover, the CT value could be used to estimate EHL and optimise the thyroid absorbed dose if EHL is not measured, as the CT value is correlated with EHL. However, the extent to which the use of the CT value improves the cure rate remains to be determined in future studies.
TRAb was not correlated with the CT value in this study. TRAb is a TSH receptor antibody that not only inhibits the TSH receptor but also continuously stimulates it to overproduce thyroid hormones. Therefore, it has been reported that TRAb is related to the rate of iodine metabolism, and that high TRAb levels tend to have shorter EHL [14]. Because the relationship between the thyroid CT value and EHL was demonstrated in this study, a relationship with TRAb is possible. However, the efficacy of TRAb has also been reported to change with age [15], and its relationship with thyroid-stimulating antibody (TSAb), which is reportedly a more specific parameter for Graves’ disease than is TRAb [16, 17], should also be investigated.
The present study has some limitations. First, the CT images of the patients were obtained before the initiation of treatment; however, the timing differed from that of the blood tests by approximately 1 week to 1 month. Changes, such as iodine restriction or the withdrawal of antithyroid medication, occurred in some patients during this period. However, no significant relationship with thyroid hormones was observed in the present study, as the thyroid hormones are sensitive to medication. Previous studies have reported that the CT value is weakly correlated with TSH and FT4 [4, 6]. Therefore, the timing of CT imaging and blood sampling should be aligned to accurately determine the correlation between the thyroid hormone levels and the CT value. Second, the CT value in patients with Plummer disease was calculated by including the normal areas of the thyroid gland. The CT value calculated using this measurement method was correlated with EHL. However, as the number and size of nodules may affect the CT value in different patients, it is necessary to separate nodule areas from normal thyroid areas and calculate the CT value to confirm their relationship with thyroid function. Finally, although the ROIs were set for the entire thyroid gland in the present study, some patients had low CT values, and some CT values were almost equivalent to those of the surrounding soft tissues. Determining the thyroid contour in such patients was difficult, which may have contributed to errors in the calculation of the CT value. As the ROIs were set by a single nuclear medicine specialist in the present study, inter-examiner errors were not examined. In addition, artefacts may have appeared owing to the influence of the clavicle and jaw, which may have changed the CT value. Such effects are considered to be one of the factors causing errors in the calculation of the CT value.
Conclusions
This study investigated the relationship between the CT value and the function and volume of the thyroid gland by exploring the factors related to the changes in the CT value in patients with hyperthyroidism. The CT value exhibited a significant correlation with EHL, suggesting that the CT value reflects thyroid function and is mainly related to the factors associated with iodine discharge.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.
Abbreviations
- CT:
-
Computed tomography
- EANM:
-
European association of nuclear medicine
- EHL:
-
Effective half-life
- FT3:
-
Free triiodothyronine
- FT4:
-
Free thyroxine
- HU:
-
Hounsfield units
- I-131:
-
Radioiodine
- RIU:
-
Radioiodine uptake
- TRAb:
-
TSH receptor antibody
- TSH:
-
Thyroid-stimulating hormone
References
Iida Y, Konishi J, Harioka T, Misaki T, Endo K, Torizuka K. Thyroid CT number and its relationship to iodine concentration. Radiology. 1983;147:793–5.
Kaneko T, Matsumoto M, Fukui K, Hori T, Katayama K. Clinical evaluation of thyroid CT values in various thyroid conditions. J Comput Tomogr. 1979;3:1–4.
Imanishi Y, Ehara N, Mori J, Shimokawa M, Sakuyama K, Ishikawa T, et al. Measurement of thyroid iodine by CT. J Comput Assist Tomogr. 1991;15:287–90.
Han YM, Kim YC, Park EK, Choe JG. Diagnostic value of CT density in patients with diffusely increased FDG uptake in the thyroid gland on PET/CT images. AJR Am J Roentgenol. 2010;195:223–8.
Imanishi Y, Ehara N, Shinagawa T, Tsujino D, Endoh I, Baba K, et al. Correlation of CT values, iodine concentration, and histological changes in the thyroid. J Comput Assist Tomogr. 2000;24:322–6.
Pandey V, Reis M, Zhou YH. Correlation between computed tomography density and functional status of the thyroid gland. J Comput Assist Tomogr. 2016;40:316–9.
Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375:1552–65.
Chapman EM. History of the discovery and early use of radioactive iodine. JAMA. 1983;250:2042–4.
Hertz S, Roberts A, Salter WT. Radioactive iodine as an indicator in thyroid physiology. IV. The metabolism of iodine in Graves’ disease. J Clin Invest. 1942;21(1):25–9.
Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002;29:1118–24.
Grosso M, Traino A, Boni G, Banti E, Della Porta M, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm. 2005;20:218–23.
Campennì A, Avram AM, Verburg FA, Iakovou I, Hänscheid H, de Keizer B, et al. The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2023;50:3324–48.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–8.
Listewnik MH, Piwowarska-Bilska H, Jasiakiewicz K, Birkenfeld B. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves’ disease patients. Adv Clin Exp Med 2021;30:913–21.
Watanabe S, Okamoto S, Akikawa K, Miyamoto N, Okamura-Kawasaki M, et al. Identification of patients with Graves’ disease who benefit from high‑dose radioactive iodine therapy. Ann Nucl Med 2022;36:923–30.
Lu L, Gao C, Zhang N. Age moderates the associations between TRAbs, free T3 and outcomes of Graves’ disease patients with radioactive iodine treatment. Clin Endocrinol 2021;94:303–9.
Bano A, Gan E, Addison C, Narayanan K, Weaver JU, Tsatlidis V, et al. Age may influence the impact of TRAbs on thyroid function and relapse-risk in patients With Graves disease. J Clin Endocrinol 2019;104:1378–85.
Acknowledgements
The authors thank all current and former Nagoya University Hospital Nuclear Medicine Department staff who contributed to the acquisition of data included in this study.
Funding
Open Access funding provided by Nagoya University. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
KK is the guarantor of the integrity of the entire study. HI, NF, and KK contributed to the study concepts and design. HI and KK contributed to the literature research. HI, NF, and SA contributed to the clinical studies. HI, NF, and KK contributed to the experimental studies/data analysis. HI contributed to the statistical analysis. HI, NF, and KK contributed to the manuscript preparation. KK contributed to the manuscript editing. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethical Review Committee of Nagoya University Hospital and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethical Review Committee of Nagoya University Hospital (application no. 20-0033). As this study analysed clinical data retrospectively, we did not obtain informed consent directly from each patient. Instead of direct informed consent, we published the research contents on the university web page and provided an opt-out opportunity.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Iwanaga, H., Fujita, N., Abe, S. et al. Correlation between the thyroid computed tomography value and thyroid function in hyperthyroidism: a retrospective study. Ann Nucl Med 38, 659–665 (2024). https://doi.org/10.1007/s12149-024-01938-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-024-01938-0